Phase 3 Trial of VQW-765 for Social Anxiety Disorder Misses Endpoint
Vanda Pharmaceuticals' phase 3 trial for VQW-765, an investigational treatment for social anxiety disorder, missed its primary endpoint. The study showed no significant difference in distress levels between participants receiving VQW-765 and those receiving a placebo. The company is evaluating the data, and the clinical program is currently on hold.
How this was made
The 30-second read
Why it matters
Study 3201 (NCT07221578) randomized 546 adults to a single dose of VQW-765 or placebo, then assessed distress during the TSST performance phase. The primary endpoint showed no statistically significant difference in female participants, and no significant difference in the overall population. Vanda stated the clinical program is on hold pending further evaluation.
Market read
This is a direct, company-specific clinical de-risking event: a Phase 3 primary endpoint miss plus an explicit program hold.
What to watch
The article specifies the primary endpoint was distress during the TSST performance phase in females; investors may wait for additional analyses (secondary endpoints, biomarker signals, or protocol learnings) before fully writing off the program.
Background
VQW-765 is an investigational on-demand oral alpha 7 nicotinic acetylcholine receptor partial agonist being studied for social anxiety disorder (SAD).
Ticker impact
Vanda Pharmaceuticals said its Phase 3 Study 3201 for VQW-765 missed the primary endpoint and the program is on hold pending further evaluation.
Likely downside bias as investors price in reduced probability of near-term clinical success and potential program de-risking.
The article reports a Phase 3 primary endpoint miss, no statistical difference vs placebo, and an explicit clinical program hold, which are direct negative catalysts for the issuer’s development pipeline.
Market effects
Adds to negative read-through for CNS anxiety drug development and alpha-7 nAChR partial agonist programs, potentially weighing on sentiment for similar-stage peers.
Primarily US biotech sentiment; limited direct regional spillover beyond listed CNS-focused developers.
Modest global impact, mainly through investor sentiment toward psychiatric disorder drug pipelines rather than broad macro or regulatory shifts.
Counterpoint
A Phase 3 miss does not necessarily end the platform; the company may still identify subgroups, dosing, or endpoint refinements that could revive value.
Key entities
- drugVQW-765
Investigational on-demand oral alpha 7 nAChR partial agonist for social anxiety disorder.
- companyVanda Pharmaceuticals
Developer of VQW-765; reported Phase 3 Study 3201 missed its primary endpoint and placed the program on hold.
- clinical_trialStudy 3201 (NCT07221578)
Phase 3 trial evaluating VQW-765 in adults with social anxiety disorder using TSST distress as the primary endpoint.
